JenaValve today announced new clinical findings for its Trilogy TAVR system shared last week at the New York Valves 2026 ...
New Evidence Further Defines Distinct Clinical Considerations for Transcatheter Aortic Valve Replacement (TAVR) in Aortic Regurgitation (AR) and ...
MedPage Today on MSN
JenaValve TAVR device promising for LVAD-associated aortic regurgitation
Good results reported with emergency-use and compassionate-use cases ...
IRVINE, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- JenaValve Technology, Inc., developer and manufacturer of the Trilogy™ Transcatheter Heart Valve (THV) System, today announced highlights from the ...
JenaValve’s Trilogy transcatheter aortic valve replacement device for severe aortic regurgitation (TAVR-AR) treatment has obtained pre-market approval (PMA) from the US Food and Drug Administration ...
JenaValve is showing significant progress in the plan to get its transcatheter aortic valve replacement (TAVR) system approved. FDA granted the Irvine, CA-based company Breakthrough Device Designation ...
IRVINE, Calif.--(BUSINESS WIRE)--JenaValve Technology, Inc., a developer, manufacturer and marketer of next-generation transcatheter aortic valve repair (TAVR) systems for the treatment of aortic ...
JenaValve’s Series C swells to nearly $100M for its TAVI implants that treat cardiovascular stenosis
JenaValve Technology just added another $26.5 million to its expanding Series C round, which looks to have swelled to near $100 million. The financing round was led by RMM and Valiance, and included ...
MUNICH, & IRVINE, Calif.--(BUSINESS WIRE)--JenaValve Technology, Inc., a developer, manufacturer and marketer of next-generation transcatheter aortic valve repair (TAVR) systems for the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results